Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (365)	4/9/2003 11:57:10 AM
From: tuck	Respond to of 508

Mr. Market unimpressed by this, nevertheless, we can mark our calendars: >>BRISBANE, Calif., April 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - News) announced today that results of a randomized, double-blind, placebo-controlled Phase II clinical trial evaluating Actimmune's® (interferon gamma-1b) influence on several underlying mechanisms of action in idiopathic pulmonary fibrosis (IPF) will be presented at the 99th Annual Conference of the American Thoracic Society (ATS) next month in Seattle. The molecular measures associated with IPF, a debilitating and fatal lung disease, include measures of fibrosis, antimicrobial activity, growth factors and inhibitors of angiogenesis. Full results of this trial, which involved 32 patients, will be presented on Sunday, May 18, at ATS in Seattle by Robert M. Strieter, M.D., Professor of Medicine and Pathology and Chief, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA in Los Angeles. "The purpose of this trial was to understand the biological basis for interferon gamma-1b treatment in IPF and extend our knowledge of its effects in IPF at the molecular level," said Dr. Strieter. "These results help provide a plausible hypothesis for the mechanism of action of interferon gamma-1b in IPF. We are excited by these results and look forward to sharing them in more detail at the ATS meeting in May."<< snip Cheers, Tuck